Depression and Anxiety Center, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Curr Top Behav Neurosci. 2022;58:467-489. doi: 10.1007/7854_2022_357.
Anhedonia - the reduced ability to experience or respond to pleasure - is an important symptom domain for many psychiatric disorders. It is particularly relevant to depression and other mood disorders and it is a diagnostic criterion of a major depressive episode. Developing safe and effective pharmacological interventions for anhedonia is a critical public health need. The current chapter will review the state of the field with respect to both the efficacy of currently available pharmacotherapies for anhedonia and the recent clinical research focusing on new brain targets, including the kappa-opioid receptor and the KCNQ2/3 receptors. The evidence for anti-anhedonic effects of ketamine and psychedelic agents will be reviewed, as well.
快感缺失——体验或回应愉悦的能力降低——是许多精神障碍的一个重要症状领域。它与抑郁症和其他情绪障碍尤其相关，也是重性抑郁发作的一个诊断标准。开发安全有效的治疗快感缺失的药物干预措施是一个至关重要的公共卫生需求。本章将回顾目前针对快感缺失的现有药物治疗的疗效以及最近专注于新的大脑靶点的临床研究的状况，包括 κ 阿片受体和 KCNQ2/3 受体。也将回顾氯胺酮和迷幻剂的抗快感缺失作用的证据。
